Gilead Sciences's most recent trend suggests a bullish bias. One trading opportunity on Gilead Sciences is a Bull Put Spread using a strike $70.00 short put and a strike $65.00 long put offers a potential 20.19% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $70.00 by expiration. The full premium credit of $0.84 would be kept by the premium seller. The risk of $4.16 would be incurred if the stock dropped below the $65.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Gilead Sciences is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Gilead Sciences is bullish.
The RSI indicator is at 73.4 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
3 Charts That Show Why to Buy Gilead Sciences Stock Now
Sun, 02 Jul 2017 15:01:00 +0000
Why buy Gilead Sciences stock? These charts tell the story.
Here are four 4th of July stocks to light up your portfol…
Fri, 30 Jun 2017 21:26:00 +0000
The “Fast Money” traders discuss their final trades for the day including Avid Budget Group, Decker Outdoor Corp, Gilead Sciences and Twitter.
Gilead And Vertex Should Join — But Don't Hold Your Breath: Analyst
Fri, 30 Jun 2017 20:13:46 +0000
Gilead would be better of acquiring Vertex than an oncology asset like Tesaro or Incyte, an analyst suggested Friday.
Yes, Gilead Should Buy Vertex
Fri, 30 Jun 2017 13:34:00 +0000
The arrow is stopping on M&A. With its hepatitis-C business slowing, Gilead “needs a transformational acquisition soon to prop up its falling revenue and growth outlook,” claim Leerink's Geoffrey Porges and Bradley Canino. Gilead currently has ~$32bn in cash and a leverage ratio of ~1.2x, suggesting that the company has the potential to comfortably make a transformative acquisition such as Vertex.
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Fri, 30 Jun 2017 10:00:00 +0000
These prescription drugs raked in billions of dollars last year. But several of them might not be so lucrative for much longer.
Also on Market Tamer…
Follow Us on Facebook